BMNR Trading Analysis - 10/05/2026 02:59 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for BMNR (a micro-cap biotech / speculative issuer with high beta characteristics):

• BMNR has been highlighted in prior quarters for volatile clinical-stage pipeline updates, with no confirmed Phase 3 readouts scheduled in early October 2026.
• No material earnings catalyst confirmed before the next major options expiration (2026-11-20); fiscal year end was 2026-08-01 per fundamentals.
• High-beta small caps have faced broad sector rotation pressure amid rising rate uncertainty, consistent with BMNR's beta of 3.65.
• Recent headlines around meme-stock-style volume spikes in similar tickers may have contributed to elevated historical volatility (81.64%).
• No verified LIVE X posts were retrieved for this run; sentiment context is limited to embedded options flow.

Context note: The above is external knowledge framing only. All technical, fundamental, and sentiment analysis below is strictly from embedded data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS JSON (source: FinWin fundamentals local, as of 2026-10-05):

• Trailing P/E: 2.40 — extremely low, but trailing EPS is negative at -4.29, indicating the company is not profitable on a TTM basis.
• PEG ratio: null; forward P/E: null; price-to-book: null — no growth or book-value valuation metrics available.
• Revenue growth, gross/operating/net margins, ROE, debt-to-equity, and free cash flow: all null — not disclosed in data.
• Market cap: $16,112,166,460.00; shares out: 603,226,000.00; institutional ownership: 26.21% (low sponsorship).
• Dividend yield: 0.04% (rate $0.01); ex-div 2025-12-05 — negligible income factor.
• Beta: 3.65; 52-week range: $12.80 – $65.60; current price ~$26.72 (intraday 10/05) well below midpoint of 52-wk range.
• Historical volatility: 81.64%; average volume: 39,483,000.00 — highly speculative profile.
• Analyst consensus / target mean price: null (no analyst opinions in data).

Fundamental alignment: Negative EPS and missing profitability metrics contrast with a low trailing P/E (distorted by losses). Technically, price sits above 50-day SMA ($22.53) but below recent daily closes near $28; fundamentals do not support a value thesis, only a speculative volatility one.

Current Market Position

From minute bars (2026-10-02 09:30 to 2026-10-05 14:30) and daily history:

• Daily close 2026-10-02: $26.29; intraday last bar 2026-10-05 14:30: $26.72 (open $26.69, high $26.72, low $26.69).
• First 5 mins 10/02: opened $27.56, slid to $27.26 by 09:55 — early selling pressure.
• Last 5 mins 10/05: steady climb $26.58 → $26.72 on low volume (69k–174k/bar) — weak late-session uptick.
• Daily range 10/02: high $28.20, low $25.92 — closed near lower half.
• 30-day range (indicators): high $28.86, low $21.90 — current $26.29 (10/02) sits ~41% up the range.

Technical Analysis

• SMA alignment: Price ($26.29) < SMA5 ($26.61) but > SMA20 ($25.92) > SMA50 ($22.53) — short-term soft, medium/long bullish.
• RSI 52.03: neutral, no overbought/oversold extremes.
• MACD (1.23) > signal (0.98), hist +0.25: mild bullish momentum, no bear divergence in data.
• Bollinger: price inside bands, mid $25.92; no squeeze flagged (width ~$6.57).
• 30-day context: price $26.29 within $21.90–$28.86; room to upper band $29.21.

True Sentiment Analysis (Delta 40-60 Options)

From BMNR_options_20261005_1459.json (methodology: Delta 40-60 only):

Call Dollar Volume: $2,619,863.00 (52.1%) Put Dollar Volume: $2,409,655.00 (47.9%) Total: $5,029,518.00

• Sentiment: Balanced (call 52.1% / put 47.9%).
• Call contracts: 15,678 vs put 3,528 — high call count but lower $ vol share due to strike mix.
• Pure directional conviction: near-neutral; no skew beyond noise.
• Divergence: technicals mildly bullish (MACD+, SMA50 support) yet options flow balanced — no aggressive directional bet.

Key Price Levels (Observational Only)